Charles River Laboratories (CRL) Tops Q1 EPS by 19c; raises guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $278.06 -1.28%
Revenue Growth %: -4.2%
Financial Fact:
Selling, general and administrative: 85.65M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -4.2%
Financial Fact:
Selling, general and administrative: 85.65M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.78, $0.19 better than the analyst estimate of $2.59. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $986.31 million.
GUIDANCE:
Charles River Laboratories sees FY2023 EPS of $9.90-$10.90, versus the consensus of $10.24.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
